JPRN-UMIN000017453已完成1 期
Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors - Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors
atural Center for Basic Research and Development, Hiroshima University0 个研究点目标入组 3 人开始时间: 2015年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
This study was ended becasue the objected cases were enrolled and no DLTs appeared. The safety of dose of temsirolimus (35 mg/m2) with the combination of Vincristin and Irrinotecan was confirmed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1days-old 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •active double cancer severe infection abnormal ECG findings intestinal pneumonia etc.
研究者
相似试验
已完成
1 期
Combination therapy with immune-cell therapy and immune check point inhibitor.malignant tumorJPRN-jRCTc031210185Takimoto Rishu3
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190100Takimoto Rishu40
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190098Takimoto Rishu40
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190099Takimoto Rishu40
已完成
不适用
Randomized trial of telmisartan and/or enalapril on renoprotective effects for patients of chronic renal diseases with hypertension.Chronic Kidney DiseasesJPRN-C000000299Institute of Clinical Medicine, University of Tsukuba150